OTCPK:BOAA

Stock Analysis Report

Executive Summary

Bio-America Inc. operates as a biotechnology company that researches and develops drug- screening technologies for manufacturing anti-obesity, anti-infective, and oncology products.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • No data on Bio-America's last earnings update.
  • Bio-America is not covered by any analysts.

Share Price & News

How has Bio-America's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:BOAA

1.3%

US Healthcare

1.2%

US Market


1 Year Return

n/a

OTCPK:BOAA

-8.2%

US Healthcare

1.7%

US Market

No trading data on BOAA.

No trading data on BOAA.


Share holder returns

BOAAIndustryMarket
7 Day0%1.3%1.2%
30 Day0%-0.7%4.9%
90 Day0%0.01%3.7%
1 Yearn/a-6.8%-8.2%3.9%1.7%
3 Yearn/a30.1%24.9%47.2%37.7%
5 Yearn/a63.5%53.8%60.0%42.4%

Price Volatility Vs. Market

How volatile is Bio-America's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Bio-America undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Bio-America is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Bio-America has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Bio-America's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Bio-America regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Bio-America expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bio-America has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Bio-America performed over the past 5 years?

0.1%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Bio-America has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Bio-America's financial position?


In this section we usually analyse Bio-America's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Bio-America has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of BOAA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Bio-America's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Bio-America's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Bio-America's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Bio-America's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Bio-America has not reported any payouts.

Unable to verify if Bio-America's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Bio-America has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Bio-America's salary, the management and board of directors tenure and is there insider trading?


CEO

Bio-America has no CEO, or we have no data on them.


Insider Trading

No 3 month insider trading information.


Management Team

  • Tom Stevens

    President

    • Tenure: 0yrs

Board Members

  • Enoch Braude

    Director

    • Tenure: 0yrs

Company Information

Bio-America Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bio-America Inc.
  • Ticker: BOAA
  • Exchange: OTCPK
  • Founded: 1999
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: US$297.000k
  • Shares outstanding: 297.00k
  • Website: https://null

Location

  • Bio-America Inc.
  • 497 Soudan Avenue
  • Toronto
  • Ontario
  • M4S 1X1
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BOAAOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJun 2003

Biography

Bio-America Inc. operates as a biotechnology company that researches and develops drug- screening technologies for manufacturing anti-obesity, anti-infective, and oncology products. The company was founded ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/06/11 03:30
End of Day Share Price2019/03/13 00:00
EarningsN/A
Annual EarningsN/A


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.